Thu, Mar 25 | Webinar

Contextual Reprogramming of CAR-T Cells for the Treatment of HER2-Expressing Cancers

Combining checkpoint inhibition (CPI) to adoptive cell therapy (ACT) may prevent engineered chimeric antigen receptor (CAR)-T cell exhaustion and improve outcomes. However, cumulative toxicities and costs limit this approach.
Tickets Are Not on Sale
Contextual Reprogramming of CAR-T Cells for the Treatment of HER2-Expressing Cancers

Time & Location

Mar 25, 10:00 AM CDT
Webinar

Share this event